Veskon
Back to feed
Lead dossierLanded01:21

BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for HCPs | Safety Info

braf-metastatic-nsclc-hcp-rx.com · Discovered 1 hr. ago

Hot leadOther
Visit site

Summary

See safety information of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib), a combination treatment for adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.

Audience
General
Category
Other
Country
Unknown
Status
Live

Technology stack

ReactCloudflareHosting: Cloudflare